North America Cancer Immunotherapy Market Size & Outlook
North America cancer immunotherapy market, 2018-2030 (US$M)
Related Markets
North America cancer immunotherapy market highlights
- The North America cancer immunotherapy market generated a revenue of USD 55,792.8 million in 2023.
- The market is expected to grow at a CAGR of 7.3% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 55,792.8 million |
| Market revenue in 2030 | USD 91,565.6 million |
| Growth rate | 7.3% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Oncolytic Viral Therapies and Cancer Vaccines |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines |
| Key market players worldwide | Pfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR |
Other key industry trends
- In terms of revenue, North America region accounted for 44.4% of the global cancer immunotherapy market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 59,131.5 million by 2030.
Monoclonal antibodies was the largest segment with a revenue share of 67.06% in 2023. Horizon Databook has segmented the North America cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
High growth of the cancer immunotherapy market in North America can be attributed to various factors, such as rise in burden of cancer and increase in number of favorable government initiatives. Funding for cancer research is high in the region. Moreover, increasing demand for personalized medicines is expected to positively impact growth of the North American cancer immunotherapy market.
Moreover, government regulations in North America support R&D for novel cancer immune therapeutics. Major players operating in this market are Merck & Co., Inc.; Bristol-Myers Squibb Company; and F. Hoffmann-La Roche Ltd. Presence of some of the leading companies is expected to increase availability of cancer immune therapeutics in the region.
For instance, in May 2017, the U.S. FDA approved Keytruda (Merck & Co., Inc.) for cancer patients with certain specific biomarkers. North America holds a major market share, especially the U.S., due to increasing awareness about the potential of immunotherapy and targeted therapy. This factor has driven the U.S.-based firms to make considerable investments in the development of novel drugs.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Immunotherapy Market Scope
Cancer Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America cancer immunotherapy market size, by country, 2018-2030 (US$M)
North America Cancer Immunotherapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
